These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1805560)

  • 1. Genetic approaches to a vaccine for pertussis.
    Nencioni L; Pizza M; Volpini G; Podda A; Rappuoli R
    Adv Exp Med Biol; 1991; 303():119-27. PubMed ID: 1805560
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of non-toxigenic vaccine strains of Bordetella pertussis by gene replacement.
    Cockle S; Zealey G; Loosmore S; Yacoob R; Fahim R; Yang YP; Jackson G; Boux H; Boux L; Klein M
    Adv Exp Med Biol; 1991; 303():221-5. PubMed ID: 1805567
    [No Abstract]   [Full Text] [Related]  

  • 3. Engineering bacterial toxin for the development of new vaccine against pertussis.
    Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
    Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
    Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
    Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.
    Boucher P; Sato H; Sato Y; Locht C
    Infect Immun; 1994 Feb; 62(2):449-56. PubMed ID: 7507893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and characterization of genetically inactivated pertussis toxin.
    Brown DR; Keith JM; Sato H; Sato Y
    Dev Biol Stand; 1991; 73():63-73. PubMed ID: 1778335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The advent of recombinant pertussis vaccines.
    Burnette WN
    Biotechnology (N Y); 1990 Nov; 8(11):1002-5. PubMed ID: 1366927
    [No Abstract]   [Full Text] [Related]  

  • 8. Further contributions to an improved pertussis vaccine: II. New findings in the development of a pertussis vaccine.
    Robbel L; Hungerer KD; Aktories K
    Behring Inst Mitt; 1984 Nov; (76):110-2. PubMed ID: 6098261
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical trials of acellular pertussis vaccine in Sweden. An attempt to solve the problem of pertussis vaccination.
    Olin P
    Ann Sclavo Collana Monogr; 1986; 3(1-2):165-72. PubMed ID: 2892504
    [No Abstract]   [Full Text] [Related]  

  • 10. Engineering bacterial toxins for the development of a new vaccine against whooping cough.
    Bartoloni A; Pizza M; Tagliabue A; Rappuoli R
    Pharmacol Res; 1989; 21 Suppl 2():19-25. PubMed ID: 2483586
    [No Abstract]   [Full Text] [Related]  

  • 11. Towards third-generation whooping cough vaccines.
    Rappuoli R; Pizza M; Podda A; De Magistris MT; Nencioni L
    Trends Biotechnol; 1991 Jul; 9(7):232-8. PubMed ID: 1370047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
    Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK
    Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acellular pertussis vaccines: a turning point in infant and adolescent vaccination.
    Rappuoli R
    Infect Agents Dis; 1996 Jan; 5(1):21-8. PubMed ID: 8789596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational design of vaccines.
    Rappuoli R
    Nat Med; 1997 Apr; 3(4):374-6. PubMed ID: 9095163
    [No Abstract]   [Full Text] [Related]  

  • 15. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.
    Hegerle N; Guiso N
    Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of whooping cough bacterium may reduce vaccine effectiveness.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(6):1430. PubMed ID: 25396233
    [No Abstract]   [Full Text] [Related]  

  • 17. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
    Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
    Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
    Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
    Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Japanese clinical trials with Takeda acellular pertussis vaccine.
    Kuno-Sakai H; Kimura M; Ozaki K; Isomura S; Kamiya H; Nii R; Kato T; Horiuchi K; Syukuda Y; Fujita I
    Tokai J Exp Clin Med; 1988; 13 Suppl():15-9. PubMed ID: 2908519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of pertactin in pertussis vaccines: the jury is still out.
    Desauziers E; Danve B; Decker MD; Veitch K
    J Infect Dis; 2004 Apr; 189(7):1332-3; author reply 1333-5. PubMed ID: 15031804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.